Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A series of papers which reviewed portable devices to detect poor quality medicines has concluded major gaps in scientific evidence remain a key barrier for regulators to implement surveillance systems using such devices.

Medicine Quality Research Group at MORU, headed by Dr Celine Caillet

Poor quality medical products jeopardise national, regional and global attempts to improve access to effective health care because they lead to avoidable morbidity and mortality, waste human and financial resources, and contribute to drug resistance. WHO estimates that globally 1 in 10 medical products is substandard/falsified, but the reality is that their detailed epidemiology remains unclear because of the difficulties of detecting them in supply chains and communities.

The Medicine Quality Research Group (LOMWRU, Lao PDR) of IDDO and MORU conducted an independent evaluation and comparison of portable devices to provide evidence to facilitate decisions about whether these new technologies are appropriate for screening of medicines in their countries and they should be deployed.

This work has been described in this series of five papers, published in PLOS Neglected Tropical Diseases:

The full story is available on the IDDO website